Concept
GLP-1 receptor agonists
GLP-1 receptor agonists are drugs that activate the glucagon-like peptide-1 receptor to increase glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite—used mainly in type 2 diabetes and obesity, with expanding off-label and safety questions.
Students often treat “GLP-1 drugs” as one claim. Efficacy as insulin add-on, pancreatitis safety signals, and neuropsychiatric repurposing answer different questions with different designs.
Evidence
What the evidence shows
Drawn from 3 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
A systematic/clinical synthesis evaluates glucagon-like peptide-1 receptor agonists added to insulin for type 1 diabetes—glucose and weight outcomes under insulin co-therapy.
- Do GLP-1 drugs show pancreatitis safety signals?— pancreatitis case series ≠ T1D efficacy trial
Study Role Design N Population Outcome Do GLP-1 drugs help as add-ons in type 1 diabetes? Supports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Do GLP-1 drugs show pancreatitis safety signals? Qualifiespancreatitis case series ≠ T1D efficacy trial OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
A case-series analysis associates specific GLP-1 receptor agonists with acute pancreatitis reports—useful for safety signal literacy, not incidence rates.
- Do GLP-1 drugs help as add-ons in type 1 diabetes?— efficacy add-on ≠ spontaneous pancreatitis reports
Study Role Design N Population Outcome Do GLP-1 drugs show pancreatitis safety signals? Supports OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Do GLP-1 drugs help as add-ons in type 1 diabetes? Qualifiesefficacy add-on ≠ spontaneous pancreatitis reports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Semaglutide/liraglutide are being explored beyond glycemic control (e.g., alcohol use disorder).
Repurposing work examines semaglutide and liraglutide for alcohol use disorder—illustrating that receptor class claims travel across indications carefully.
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Study Role Design N Population Outcome Do GLP-1 drugs help as add-ons in type 1 diabetes? Supports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Do GLP-1 drugs show pancreatitis safety signals? Supports OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents
Common misconceptions
All GLP-1 drugs have identical safety and efficacy profiles.
Agent, dose, indication, and study design differ; class talk is a starting map, not a result.
A pancreatitis case series measures how common pancreatitis is on GLP-1RAs.
Case series and spontaneous reports cannot estimate incidence without denominators and controls.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
What does a GLP-1RA primarily activate?
The glucagon-like peptide-1 receptor (incretin pathway).
Why can’t a case series alone prove pancreatitis incidence?
It lacks a defined denominator/control comparison for rates.
The studies
3 studies in this library bear on GLP-1 receptor agonists, ordered by citations.
- Do GLP-1 drugs lower AUD hospitalizations?
In 227,866 Swedes with AUD, semaglutide (aHR 0.64) and liraglutide (aHR 0.72) use periods had lower AUD hospitalization risk than nonuse—stronger than approved AUD meds overall.
- Do GLP-1 drugs help as add-ons in type 1 diabetes?
Across 11 RCTs (2,856 adults), GLP-1 RA add-on therapy modestly lowered HbA1c (−0.21%), weight (−4.04 kg), and insulin doses without more severe hypo/DKA, but GI adverse events rose (OR 2.96).
- Do GLP-1 drugs show pancreatitis safety signals?
Across 6,751 FAERS ICSRs (plus 39 case-series patients), AP reporting signals appeared for all studied GLP-1 RAs, especially exenatide and liraglutide.
Learn alongside
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published